Raymond E. Cabillot Sells 5,381 Shares of Pro-Dex, Inc. (NASDAQ:PDEX) Stock

Pro-Dex, Inc. (NASDAQ:PDEX) Director Raymond E. Cabillot sold 5,381 shares of the firm’s stock in a transaction on Tuesday, January 28th. The shares were sold at an average price of $41.64, for a total value of $224,064.84. Following the transaction, the director now owns 319,752 shares in the company, valued at approximately $13,314,473.28. This trade represents a 1.66 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Pro-Dex Stock Up 3.5 %

Shares of NASDAQ:PDEX opened at $43.26 on Thursday. Pro-Dex, Inc. has a 1 year low of $16.18 and a 1 year high of $59.60. The company has a market capitalization of $140.98 million, a PE ratio of 28.09 and a beta of 0.56. The business has a fifty day moving average price of $47.68 and a two-hundred day moving average price of $34.28. The company has a debt-to-equity ratio of 0.36, a current ratio of 3.41 and a quick ratio of 1.94.

Hedge Funds Weigh In On Pro-Dex

A number of hedge funds and other institutional investors have recently made changes to their positions in PDEX. FMR LLC raised its position in Pro-Dex by 34.9% in the third quarter. FMR LLC now owns 3,973 shares of the medical instruments supplier’s stock worth $119,000 after acquiring an additional 1,028 shares during the period. Ritholtz Wealth Management purchased a new stake in shares of Pro-Dex during the 4th quarter worth approximately $572,000. Renaissance Technologies LLC increased its stake in shares of Pro-Dex by 7.9% during the 2nd quarter. Renaissance Technologies LLC now owns 12,240 shares of the medical instruments supplier’s stock worth $240,000 after purchasing an additional 900 shares during the last quarter. Bard Associates Inc. raised its holdings in shares of Pro-Dex by 17.6% in the 3rd quarter. Bard Associates Inc. now owns 13,596 shares of the medical instruments supplier’s stock worth $406,000 after purchasing an additional 2,031 shares during the period. Finally, JPMorgan Chase & Co. lifted its stake in Pro-Dex by 2.2% in the third quarter. JPMorgan Chase & Co. now owns 24,790 shares of the medical instruments supplier’s stock valued at $740,000 after purchasing an additional 529 shares during the last quarter. 15.28% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on PDEX. Ascendiant Capital Markets raised their price target on shares of Pro-Dex from $30.00 to $52.00 and gave the company a “buy” rating in a research report on Monday, November 11th. StockNews.com raised shares of Pro-Dex from a “buy” rating to a “strong-buy” rating in a research report on Saturday, December 14th.

Pro-Dex Company Profile

Pro-Dex, Inc designs, develops, manufactures, and sells powered surgical instruments for medical device original equipment manufacturers worldwide. The company offers autoclavable, battery-powered and electric, and multi-function surgical drivers and shavers that are primarily used in the orthopedic, thoracic, and craniomaxillofacial markets.